Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
154 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Arthritis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Arthritis - Pipeline Review, H2 2014', provides an overview of the Arthritis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Arthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Arthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Arthritis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Arthritis Overview 8 Therapeutics Development 9 Pipeline Products for Arthritis - Overview 9 Pipeline Products for Arthritis - Comparative Analysis 10 Arthritis - Therapeutics under Development by Companies 11 Arthritis - Therapeutics under Investigation by Universities/Institutes 15 Arthritis - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Arthritis - Products under Development by Companies 20 Arthritis - Products under Investigation by Universities/Institutes 22 Arthritis - Companies Involved in Therapeutics Development 23 Eli Lilly and Company 23 GlaxoSmithKline plc 24 Nemucore Medical Innovations, Inc. 25 Taisho Pharmaceutical Co., Ltd. 26 Sylentis S.A. 27 Astellas Pharma Inc. 28 Eisai Co., Ltd. 29 Bone Medical Limited 30 Momenta Pharmaceuticals, Inc. 31 Can-Fite BioPharma Ltd. 32 Lexicon Pharmaceuticals, Inc. 33 CSL Limited 34 WhanIn Pharmaceutical Co., Ltd. 35 Oscotec Inc. 36 Viron Therapeutics, Inc. 37 PLx Pharma Inc. 38 Endocyte, Inc. 39 Cardax Pharmaceuticals, Inc. 40 Taiwan Liposome Company, Ltd. 41 NasVax Ltd. 42 CalciMedica, Inc. 43 Zyngenia, Inc. 44 SelectX Pharmaceuticals, Inc. 45 DoNatur GmbH 46 CellAct Pharma GmbH 47 Arcarios BV 48 Inbiopro Solutions Pvt. Ltd. 49 Sagene Pharmaceuticals, Inc. 50 vida therapeutics inc. 51 Dong-A Socio Group 52 Arthritis - Therapeutics Assessment 53 Assessment by Monotherapy Products 53 Assessment by Combination Products 54 Assessment by Target 55 Assessment by Mechanism of Action 59 Assessment by Route of Administration 63 Assessment by Molecule Type 65 Drug Profiles 67 vancomycin hydrochloride - Drug Profile 67 PL-1100 - Drug Profile 68 MCS-18 - Drug Profile 69 GLPG-0555 - Drug Profile 71 LY-3114062 - Drug Profile 72 CSL-324 - Drug Profile 73 VT-346 - Drug Profile 74 CF-602 - Drug Profile 75 CDX-085 - Drug Profile 76 PL-5100 - Drug Profile 78 EC-1496 - Drug Profile 79 AMAP-102 - Drug Profile 80 ABC-294640 - Drug Profile 82 Anti-CD3 Oral Immunotherapy - Drug Profile 84 IBPB-001PH - Drug Profile 86 selegiline + NSAIDs - Drug Profile 87 AS-1940477 - Drug Profile 88 dexamethasone acetate - Drug Profile 89 MDC-917 - Drug Profile 90 Small Molecules to Inhibit MMP - Drug Profile 91 CAP-2.1 - Drug Profile 92 CAP-2.2 - Drug Profile 93 CAP1.1 - Drug Profile 94 Recombinant Protein to Inhibit TNF-Alpha for Inflammatory Diseases - Drug Profile 95 Small Molecules to Inhibit C-Rel for Central Nervous System, Musculoskeletal, Respiratory and Metabolic Disorders - Drug Profile 96 OXT-328 - Drug Profile 97 Peptide to Inhibit Intracellular IL-1 Receptor for Musculoskeletal, Dermatology and Central Nervous System Disorders - Drug Profile 99 Peptides to Inhibit MHC Class I and II for CNS Disorders and Musculoskeletal - Drug Profile 100 Antibody for Autoimmune Disorders and Inflammation - Drug Profile 101 DCB-3503 - Drug Profile 102 AT-132 - Drug Profile 103 TASP-0415914 - Drug Profile 104 fluticasone propionate - Drug Profile 105 Monoclonal Antibody to Inhibit Ang-2 and TNF-a - Drug Profile 106 CIIF-4 - Drug Profile 107 OA-1 - Drug Profile 108 TLC-599 - Drug Profile 109 Monoclonal Antibody to Inhibit CCL20 for Arthritis and Contact Hypersensitivity - Drug Profile 110 Small Molecule to Activate S100A8 for Arthritis - Drug Profile 111 CM-3457 - Drug Profile 112 Drugs to Activate P58IPK for Arthritis - Drug Profile 113 IMSB-001 - Drug Profile 114 RNAi Oligonucleotide for Arthritis and Gastrointestinal Disorders - Drug Profile 115 BN-005 - Drug Profile 116 BN-008 - Drug Profile 117 Small Molecule to Inhibit SYK for Arthritis - Drug Profile 118 Small Molecule to Inhibit ADAMTS-5 for Arthritis - Drug Profile 119 WIP-901C - Drug Profile 120 Small Molecules to Inhibit Cyclophilins - Drug Profile 121 Drug for Chronic Inflammatory Diseases - Drug Profile 123 Peptides to Inhibit Fibrinogen and ICAM-1 for Oncology, Inflammtion, Arthritis, Cardiovascular Disease and Bleeding Disorders - Drug Profile 124 Peptides to Inhibit TNF-a for Immunology, Oncology and Musculoskeletal Disorders - Drug Profile 125 Small Molecules to Inhibit CD147 for Immunology, Oncology, Womens Health and Musculoskeletal Disorders - Drug Profile 126 Small Molecules to Modulate BMP-2 for Arthritis - Drug Profile 127 FIV-based siRNA - Drug Profile 128 Gene Therapy for Arthritis - Drug Profile 129 NMI-4100 - Drug Profile 130 Arthritis - Recent Pipeline Updates 131 Arthritis - Dormant Projects 135 Arthritis - Discontinued Products 137 Arthritis - Product Development Milestones 138 Featured News & Press Releases 138 Appendix 149 Methodology 149 Coverage 149 Secondary Research 149 Primary Research 149 Expert Panel Validation 149 Contact Us 150 Disclaimer 150
List of Tables Number of Products under Development for Arthritis, H2 2014 13 Number of Products under Development for Arthritis - Comparative Analysis, H2 2014 14 Number of Products under Development by Companies, H2 2014 16 Number of Products under Development by Companies, H2 2014 (Contd..1) 17 Number of Products under Development by Companies, H2 2014 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H2 2014 20 Comparative Analysis by Late Stage Development, H2 2014 21 Comparative Analysis by Clinical Stage Development, H2 2014 22 Comparative Analysis by Early Stage Development, H2 2014 23 Products under Development by Companies, H2 2014 24 Products under Development by Companies, H2 2014 (Contd..1) 25 Products under Investigation by Universities/Institutes, H2 2014 26 Arthritis - Pipeline by Eli Lilly and Company, H2 2014 27 Arthritis - Pipeline by GlaxoSmithKline plc, H2 2014 28 Arthritis - Pipeline by Nemucore Medical Innovations, Inc., H2 2014 29 Arthritis - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2014 30 Arthritis - Pipeline by Sylentis S.A., H2 2014 31 Arthritis - Pipeline by Astellas Pharma Inc., H2 2014 32 Arthritis - Pipeline by Eisai Co., Ltd., H2 2014 33 Arthritis - Pipeline by Bone Medical Limited, H2 2014 34 Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2014 35 Arthritis - Pipeline by Can-Fite BioPharma Ltd., H2 2014 36 Arthritis - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2014 37 Arthritis - Pipeline by CSL Limited, H2 2014 38 Arthritis - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2014 39 Arthritis - Pipeline by Oscotec Inc., H2 2014 40 Arthritis - Pipeline by Viron Therapeutics, Inc., H2 2014 41 Arthritis - Pipeline by PLx Pharma Inc., H2 2014 42 Arthritis - Pipeline by Endocyte, Inc., H2 2014 43 Arthritis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2014 44 Arthritis - Pipeline by Taiwan Liposome Company, Ltd., H2 2014 45 Arthritis - Pipeline by NasVax Ltd., H2 2014 46 Arthritis - Pipeline by CalciMedica, Inc., H2 2014 47 Arthritis - Pipeline by Zyngenia, Inc., H2 2014 48 Arthritis - Pipeline by SelectX Pharmaceuticals, Inc., H2 2014 49 Arthritis - Pipeline by DoNatur GmbH, H2 2014 50 Arthritis - Pipeline by CellAct Pharma GmbH, H2 2014 51 Arthritis - Pipeline by Arcarios BV, H2 2014 52 Arthritis - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 53 Arthritis - Pipeline by Sagene Pharmaceuticals, Inc., H2 2014 54 Arthritis - Pipeline by vida therapeutics inc., H2 2014 55 Arthritis - Pipeline by Dong-A Socio Group, H2 2014 56 Assessment by Monotherapy Products, H2 2014 57 Assessment by Combination Products, H2 2014 58 Number of Products by Stage and Target, H2 2014 61 Number of Products by Stage and Mechanism of Action, H2 2014 65 Number of Products by Stage and Route of Administration, H2 2014 68 Number of Products by Stage and Molecule Type, H2 2014 70 Arthritis Therapeutics - Recent Pipeline Updates, H2 2014 135 Arthritis - Dormant Projects, H2 2014 139 Arthritis - Discontinued Products, H2 2014 141
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.